Glyrova Gold Capsule is a combination pharmaceutical formulation containing Aspirin (75 mg), Rosuvastatin (10 mg), and Clopidogrel (75 mg), designed to provide comprehensive cardiovascular protection. Aspirin, an antiplatelet agent, inhibits cyclooxygenase enzymes, thereby reducing thromboxane A2 synthesis and preventing platelet aggregation, which helps in reducing the risk of myocardial infarction and stroke. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C), contributing to the prevention of atherosclerosis and cardiovascular events. Clopidogrel, another antiplatelet agent, selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet receptor, thereby inhibiting platelet activation and aggregation. The synergistic action of these three agents makes Glyrova Gold Capsule particularly useful in patients with a history of acute coronary syndrome, ischemic stroke, or established peripheral arterial disease, as well as those at high risk for cardiovascular events. It is essential to use this medication under strict medical supervision due to potential risks such as bleeding, hepatic dysfunction, and drug interactions. Regular monitoring of blood parameters and liver function tests is recommended during therapy. Glyrova Gold Capsule should be taken as prescribed to optimize cardiovascular outcomes.